Accueil   Diary - News   All news LEUKOTAC® AT THE 44TH CONGRESS OF THE EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION (EBMT)

LEUKOTAC® AT THE 44TH CONGRESS OF THE EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION (EBMT)

ELSALYS BIOTECH, a new player in immuno-oncology, will present at the 44th EBMT congress which will take place in Lisbon, Portugal, from 18 to 21 March, the progress made on LEUKOTAC® (inolimomab), its monoclonal antibody that recently demonstrated promising clinical results in the treatment of SR-aGvHD.

The company will present a poster on additional analysis of safety data of the Phase 3 study testing LEUKOTAC® vs ATG* (control arm) in 100 patients with SR-aGvHD. The data demonstrate that LEUKOTAC® represents a relevant alternative treatment, notably because of its significantly more favourable safety profile as compared to ATG. There are 3 times fewer related adverse events (AE) for all stages with LEUKOTAC® (14%) than with ATG (41%), p=0.004, as well as 2.5 times less related AE of grade 3 or higher (LEUKOTAC® 12% vs ATG 29%, p = 0.04). It is shown as well a clear decrease in potentialy life-threatening infectious episodes such as sepsis and septic shock (14% vs 24% and 4% vs 16% for the LEUKOTAC®  and ATG groups, respectively). Other major data concern the increase in overall survival at one year (+ 37%) with LEUKOTAC®, at the limit of statistical significance (HR=0.628, p=0,055 unilateral).

 

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree